COVID-19 Update: Molecular Diagnostics, Immunoassays, Vaccines, Telehealth & Other Areas - Trending Developments, Company Announcements, Analysis on Fast-Breaking Events in the COVID-19 Epidemic
DUBLIN, April 23, 2020 /PRNewswire/ -- The "COVID-19 Update: Molecular Diagnostics, Immunoassays, Vaccines, Telehealth and Other Areas" report has been added to ResearchAndMarkets.com's offering.
For years, the analyst has covered the fields of molecular diagnostics, immunoassays, vaccines, and telehealth - these all find themselves both sought-after and challenged during the current COVID-19 crisis
This report provides trending developments, company announcements, and analysis from the analysis team on the fast-breaking events in the COVID-19 epidemic.
Particular sections address the most important market changes:
Molecular Diagnostics: It's important to note that the entire molecular testing concept originated in the midst of a crisis, at that time of the AIDS crisis, and has since been brought to bear on a number of emerging and mature infectious disease categories. COVID-19 has seen the molecular in vitro diagnostics (IVD) industry bring out its best efforts in terms of fast test RT-PCR tests for their systems, point of care solutions, syndromic tests, high throughput systems and surge production on badly needed kits.
Immunoassays: Never have immunoassays been of such worldwide attention, as antibody tests are greatly sought. With this, come concerns about accuracy levels on broad populations and greater knowledge about development times. There are now immunoassays in development. We track these efforts and provide commentary on the role of these tests in a threat so far dominated by molecular diagnostics.
Vaccines: The analyst look at the vaccines in development and the struggles with vaccine discovery and manufacturing in other pandemics. Companies developing vaccines are featured.
Other Traditional IVDs: With many hospitals shut down across the globe, what is the impact and expected future of standard in vitro diagnostic testing? - from company statements made both publicly and directly to the analyst.
Remote Patient Monitoring: Already a healthcare trend that was catching on but perhaps struggling to convince payors of its critical necessity, remote patient monitoring, and telehealth transformed overnight with social distancing policies and relaxed HIPAA rules. But will market players be crowded out by traditional phone and web video companies?
This report does not seek to provide a data-driven market assessment due to the rapidly-changing situation but does provide analyst commentary that may assist customers needing to work out models. Some of the market estimates provide foundational bases on which to judge potential market impact. Commentary and analysis from the analysts who have studied markets in some cases for decades add understanding to the current, often chaotic, market atmosphere. Further publications and surveys from the analyst will provide additional market impact data.
No one company has the solution to COVID-19. Multiple companies have solutions to one problem or part of the solution, and companies are partnering to build strength and distribute products.
Key Topics Covered
Chapter One: SARS-Cov-2 Recent Developments
- Molecular Testing, So Far, Remains At Forefront
- Antibody SARS-Cov-2 Tests Move Forward
- Overall Diagnostics Testing Taking a Hit
- When Will Surgeries - and Related Diagnostic Testing - Resume?
- Asymptomatic and Presymptomatic Spread Will Focus Attention on Testing
- Continuous Introduction and Authorization of New Test Products
- Molecular DX
- Immunoassays
- Spain Provides Example of Downside of Early Serology Test
- Ancillary/Secondary Covid-19-Related Tests
- U.S. Government Response
- Congress Passes Cares Act
- HHS Awards $100M to Deal With Coronavirus, Including Testing
- Barda Funding for POC, Panels and Automated Tests
- White House Pushes Diagnostics
- Covid-19 Threat Makes for Odd Timing of Valid Act
- Background
- Defining SARS-Cov-2
- Naming the Virus
- Origins of SARS-Cov-2
- A Unique Molecular Backbone
- FDA Provides Reference Sequence Data for SARS-Cov-2
- Countermeasures in Development
- Will We See Fundamental Change in IVD?
Chapter Two: Molecular Diagnostics and SARS-Cov-2
- The Molecular Diagnostics Industry is Large and Capable
- Rapid Ramp Up After Early Stumbles
- Fast EUAs as FDA Moves to Speed Availability of Covid-19 Tests
- Twist's SARS-Cov-2 Quality Controls Added to FDA Materials
- Test Approvals
- Table: US FDA EUAs as of April 1, 2020
- Mesa Handheld Mdx Test Ships
- Syndromic Approach to Covid-19: Qiagen
- Abbott Id Now Becomes National Symbol of Poc Response
- Luminex Coronavirus Panel Gets FDA Emergency Authorization
- BGI Gets EUA for Rt-PCR Coronavirus Test
- Quidel Receives Expanded Approval
- Neumodx Coronavirus Test Gets Emergency Authorization
- T2 Adds Coronavirus Test to Panels, Per Health Network Deal
- Perkinelmer Gets Regulatory Nod in the U.S. for Coronavirus Test
- Roche Offers Multiple Commercial Kits
- Thermo Fisher Gets CE Mark for the Taqpath Covid-19 Rt-PCR Test Kit
- Mesa Biotech Gets Emergency Authorization for Poc Coronavirus Test
- Fluxergy Seeks Emergency Authorization for 1-Hour Coronavirus Test
- Genetic Signatures Seeks CE Mark for Coronavirus Diagnostic
- Emerald Organic, Todos Medical Team on Covid-19 Tests
- Bruker, Primer Design Sign European Distribution Deal for Coronavirus Test
- Impact of Large Systems and Small Poc Systems
- Molecular Point of Care
- Molecular POC Vs. Immunoassays
Chapter Three: Bottlenecks
- Practical Challenges and Scaling of Test Resources
- Test Equipment and Worker Ppe Remain An Issue
- Jama Network Calls for Creative Ideas for Increasing Ppe Supply
- Why SARS 2.0 is More Difficult to Control
- Table: Covid-19 Case Severity Scale
- SARS-Cov-2 Replication in Upper Respiratory Track Seen as Culprit
- Hais a Worry
- are Coronavirus Patients With Negative Throat Swabs Truly Virus-Free?
- Patients May Continue to Shed Virus After Symptom Clearance
- Viral Load/ Symptom Connection: Conflicting Studies
- MPOC S are Approved; Full Impact Yet to Be Seen
- Figure: FDA EUA Tests for Covid-19 by Testing Type
- Qiagen Says It Ramped Up Production to Meet Shortage of Rna Extraction Kits
Chapter Four: Covid-19 Immunoassays
- Antibody-Based Testing Taking Shape
- Policy D Pathway
- CEllex Approval
- Biomedomics
- Getting Better Guidance on Test Quality
- Serology Test Notifications
Chapter Five: Other Test Categories Impact: Critical Care, Chemistries
- Critical Care Analysis
- Blood Gas
- Critical Care Analytes: Bilirubin, Bun, Glucose
- Other Covid-19-Related Tests
- AKI Testing
Chapter Six: Vaccines and SARS-Cov-2
- Early Efforts and a First Trial Dose
- J&J Seeks to Release Covid-19 Vaccine by 2021
- Dod Grant Accelerates SARS-Cov-2 Vaccine Manufacturing
- Dynavax, Clover Partner for Protein-Based Covid-19 Vaccine
- Analysts: Technology, Not Demand Challenge
- Production Consideration
- 3D Atomic Scale Map Could AId Vaccines
Chapter Seven: Boost for Remote Patient Monitoring Seen in SARS-Cov-2 Crisis
- Congressional Action
- Hippa Penalties Relaxed
- Unique Opportunities in Telehealth/Telemedicine
- Companies in the Market
- Recent Developments
Chapter Eight: a Role for Artificial Intelligence (AI)
- Introduction
- White House Urges Researchers to Use AI to Analyze Coronavirus Papers
- Diagnostic Applications
- South Korean Firm Blends AI and Portable X-Ray Testing to Power Up Covid-19 PCR
- Persivia Releases AI-Driven Ruleset to Detect Covid-19
- Philips Intellisite Pathology Solution
- Surgisphere Rapid Test Uses AI to Diagnose Covid-19
- Biofourmis' AI-Powered Remote Monitoring Platform to Fight Covid-19
- AI as An AId in the Development of Covid-19 Therapies
Chapter Nine: Therapeutics and Covid-19
- FDA's Coronavirus Treatment Acceleration Program (Ctap)
- Snapshot for Developing Therapeutics
- Examples of CTAP in Action
- Support for CTAP
- Selected Therapeutic Approaches
- Drug Repurposing
- Car-T Support Therapeutic Finds Possible Use in Covid-19
- Kleo, Green Cross Collaborate on Covid-19 Nk Combination Therapy
- Generation Bio, Vir Partner for Mabs Against Covid-19
- Xencor, Vir Partner on Covid-19 Antibodies Research
- Frontera Supercomputer AIds Covid-19 Drug Development
- Hydroxychloroquine
Chapter Ten: Respiratory Equipment in Extreme Demand
- Ventilators
- CPAP Devices and Covid-19 Patient Usage
- CPAP as an Emergency Ventilator?
- Risk of Virus Spread and Possible Solutions
- Pulse Oximeters
- Recent EU Activity
- Cares Act
- Defense Production Act
Chapter Eleven: Research Laboratory Operations Impacted
- NIH Shifts Noncritical Research to Maintenance
- Survey: Nearly Half of All Life Science Labs Around the World are Currently Closed
- Survey: Covid-19 Causes Long-Term Disruptions to Clinical Trials
Companies Mentioned
- Abbott
- Amaro Lab of the University of California (UC), San Diego
- Avellino Lab USA
- BGI
- BioFire
- Biofourmis
- Boston Scientific
- Bruker
- Cepheid
- Clover
- Credo Diagnostics Biomedical
- Diagnostics for the Real World
- DiaSorin Molecular
- Dynavax
- Emerald Organic
- EpiGentek
- Fluxergy
- GE Healthcare
- Generation Bio
- Genetic Signatures
- GenMark Diagnostics
- Gilead Science
- Green Cross
- Hackensack Meridian Health, Center for Discovery and Innovation's (CDI)
- Henry Schein
- HiberGene Diagnostics
- Hologic
- JLK Inspection
- Johnson & Johnson (J&J)
- Kleo
- Laboratory Corporation of America (LabCorp)
- Luminex
- Medtronic
- Mesa Biotech
- Mobidiag
- Molbio Diagnostics
- NeuMoDx
- PerkinElmer
- Persivia
- Philips Medical
- Primer Design
- Qiagen
- QuantuMDx
- Quest
- Quidel
- Roche
- Surgisphere
- T2 Biosytems
- Thermo Fisher
- ThermoGenesis
- Todos Medical
- Vir
- Wadsworth Center, New York State Department of Health
- Xencor
For more information about this report visit https://www.researchandmarkets.com/r/i99t4n
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article